Onyx Pharmaceuticals, along with Bayer Healthcare Pharmaceuticals, decided to stop the trial of Nexavar tablet in the Asia-Pacific region, so that the drug is made available to all patients for use. The drug treats advanced hepatocellular carcinoma, which is the most common form of liver cancer.